Novel generations of influenza vaccines

被引：75

作者：

Kemble, G

Greenberg, H

机构：

[1] MedImmune Vaccines, Mountain View, CA 94043 USA

[2] Stanford Univ, Stanford, CA 94305 USA

来源：

VACCINE | 2003年 / 21卷 / 16期

关键词：

influenza; immunogenicity; adjuvants;

D O I：

10.1016/S0264-410X(03)00074-4

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Several strategies are being pursued to increase the quality and quantity of influenza vaccines that are used on an annual basis including increasing the immunogenicity of currently licensed inactivated vaccines, delivery of inactive vaccines directly to the nasal mucosa, the use of cell lines for virus production and the use of live, attenuated vaccines. In addition, modern molecular biological techniques are being used to create and evaluate new vaccine approaches. This report will briefly review these different strategies and outline some of the potential advantages and challenges associated with them. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

收藏

页码：1789 / 1795

页数：7

相关论文

共 58 条

[1] A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains [J].

Babai, I ;

Barenholz, Y ;

Zakay-Rones, Z ;

Greenbaum, E ;

Samira, S ;

Hayon, I ;

Rochman, M ;

Kedar, E .

VACCINE, 2001, 20 (3-4) :505-515

[2] Prevention of otitis media in children with live attenuated influenza vaccine given intranasally [J].

Belshe, RB ;

Gruber, WC .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (05) :S66-S71

[3] Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children [J].

Belshe, RB ;

Gruber, WC .

PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES, 2001, 356 (1416) :1947-1951

[4] Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine [J].

Belshe, RB ;

Gruber, WC ;

Mendelman, PM ;

Cho, I ;

Reisinger, K ;

Block, SL ;

Wittes, J ;

Iacuzio, D ;

Piedra, P ;

Treanor, J ;

King, J ;

Kotloff, K ;

Bernstein, DI ;

Hayden, FG ;

Zangwill, K ;

Yan, LH ;

Wolff, M .

JOURNAL OF PEDIATRICS, 2000, 136 (02) :168-175

[5] Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults [J].

Boyce, TG ;

Hsu, HH ;

Sannella, EC ;

Coleman-Dockery, SD ;

Baylis, E ;

Zhu, YW ;

Barchfeld, O ;

DiFrancesco, A ;

Paranandi, M ;

Culley, B ;

Neuzil, KM ;

Wright, PF .

VACCINE, 2000, 19 (2-3) :217-226

[6]

BRANDS, 1999, DEV BIOL STAND, V98, P93

[7]

Bridges Carolyn B, 2002, MMWR Recomm Rep, V51, P1

[8] Humoral and cell-mediated immunity to Vero cell-derived influenza vaccine [J].

Brühl, P ;

Kerschbaum, A ;

Kistner, O ;

Barrett, N ;

Dorner, F ;

Gerencer, M .

VACCINE, 2000, 19 (9-10) :1149-1158

[9] Adjuvantation of epidermal powder immunization [J].

Chen, DX ;

Erickson, CA ;

Endres, RL ;

Periwal, SB ;

Chu, QL ;

Shu, C ;

Maa, YF ;

Payne, LG .

VACCINE, 2001, 19 (20-22) :2908-2917

[10] Rescue of influenza A virus from recombinant DNA [J].

Fodor, E ;

Devenish, L ;

Engelhardt, OG ;

Palese, P ;

Brownlee, GG ;

García-Sastre, A .

JOURNAL OF VIROLOGY, 1999, 73 (11) :9679-9682

← 1 2 3 4 5 6 →